Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €11.50 EUR
Change Today -0.123 / -1.06%
Volume 0.0
As of 2:08 AM 08/5/15 All times are local (Market data is delayed by at least 15 minutes).

vanda pharmaceuticals inc (VM4) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/29/14 - €12.40
52 Week Low
10/13/14 - €6.51
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

vanda pharmaceuticals inc (VM4) Related Businessweek News

No Related Businessweek News Found

vanda pharmaceuticals inc (VM4) Details

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company’s products include HETLIOZ, a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt, a product for the treatment of schizophrenia. Its products also include Tradipitant, a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis; Trichostatin A, a small molecule histone deacetylase inhibitor; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

105 Employees
Last Reported Date: 07/31/15
Founded in 2002

vanda pharmaceuticals inc (VM4) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $580.0K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $360.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $360.0K
Compensation as of Fiscal Year 2014.

vanda pharmaceuticals inc (VM4) Key Developments

Vanda Pharmaceuticals Inc. Receives European Commission Approval for HETLIOZ

Vanda Pharmaceuticals Inc. announced that the European Commission approved HETLIOZ (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind adults in the European Union. The marketing authorization allows for the marketing of HETLIOZ in all 28 EU member states as well as European Economic Area members Iceland, Liechtenstein and Norway. The EC has also confirmed orphan drug designation for HETLIOZ for the treatment of Non-24 in totally blind adults.

Vanda Pharmaceuticals Seeks Acquisitions

Vanda Pharmaceuticals, Inc. (NasdaqGM:VNDA) is looking for acquisition opportunities. Vanda Pharmaceuticals has filed a shelf registration in the amount of $150 million and may also use a portion of the net proceeds to acquire or invest in businesses, products or technologies that we believe are complementary to our own, although we are not currently planning or negotiating any such transactions.

Vanda Pharmaceuticals, Inc. Announces Positive Results from the Relapse Prevention Study in Patients with Schizophrenia (REPRIEVE) Demonstrating the Long-Term Maintenance Effects of Fanapt (iloperidone)

Vanda Pharmaceuticals Inc. presented positive results from the long-term maintenance REPRIEVE (Relapse prevention study in patients with schizophrenia) clinical study at the 2015 American Society of Clinical Pharmacology (ASCP) Annual Meeting in Miami Beach, Florida. The REPRIEVE study demonstrated the ability of Fanapt (iloperidone) to prevent relapse or impending relapse in adult patients with schizophrenia as compared to placebo. In the REPRIEVE study, 79.6% of patients treated with Fanapt remained relapse free compared to 36.6% for placebo-treated patients. Vanda intends to file a supplemental New Drug Application (sNDA) for Fanapt with the U.S. Food and Drug Administration (FDA) in the second half of 2015 to include the results from the REPRIEVE study in the Fanapt package insert. The REPRIEVE study was a randomized, double-blind, placebo-controlled study to evaluate prevention of relapse in adult patients with schizophrenia receiving either flexible dose Fanapt or placebo. Study subjects were adults with schizophrenia titrated up to 12 mg/day given as 6 mg BID with open-label Fanapt and then stabilized for a further 14-24 weeks with a flexible dose Fanapt regimen (range between 8-24 mg/day daily dose given BID) as per investigator judgment. Subjects who remained clinically stable for at least 12 weeks entered the 'Relapse Prevention' phase and were randomized 1:1 to either continue on the same flexible dose regimen of Fanapt® or to withdraw from Fanapt to matched placebo in a double-blinded fashion. Subjects were followed for up to 26 weeks and were withdrawn upon showing signs of relapse or impending relapse. A predefined unblinded interim analysis was conducted after 68 relapse or impending relapse events were observed. The primary outcome was time-to-relapse or impending relapse using the interim analysis population. Of the 587 patients entering the 'Stabilization' phase, 195 (33%) met the criteria for the double-blind Relapse Prevention phase, with 99 subjects randomized to continue with Fanapt® and 96 to switch to placebo. The study was stopped early after 68 events were observed and confirmed the hypothesis that Fanapt was more effective than placebo in relapse preventions (log rank test: P < 0.0001), with a Cox regression hazard ratio estimate of 4.7 (95% confidence interval: 2.7-8.3) favoring Fanapt. The percentage of Fanapt patients remaining relapse free at the end of the double-blind Relapse Prevention phase was of 79.6% (the Kaplan-Meier estimate (KM estimate)) compared to 36.6% for placebo-treated patients. The mean time to relapse based on KM estimates was 71 days for placebo and 139 days for Fanapt subjects. The most common treatment-emergent adverse events (TEAEs) (>= 5%) suspected to be related to Fanapt in the stabilization phase were dizziness, somnolence (or sleepiness), and dry mouth. There were no Fanapt treatment-related TEAEs with a frequency >2% and higher than placebo in the double-blind Relapse Prevention phase.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VM4:GR €11.50 EUR -0.123

VM4 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,395 GBp +9.50
Bristol-Myers Squibb Co $64.84 USD -0.50
Eli Lilly & Co $84.05 USD -0.09
Pernix Therapeutics Holdings Inc $4.90 USD -0.05
Sanofi €98.85 EUR +0.68
View Industry Companies

Industry Analysis


Industry Average

Valuation VM4 Industry Range
Price/Earnings 9.8x
Price/Sales 6.7x
Price/Book 3.6x
Price/Cash Flow 8.8x
TEV/Sales 4.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VANDA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at